Article Details
Retrieved on: 2024-11-18 22:12:44
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Twist Bioscience's fiscal 2023 performance, highlighting its growth in synthetic biology, particularly DNA synthesis, and the key challenges it faces in the biopharma and biotechnology sectors, including molecular genetics and synthetic biology applications.
Article found on: www.tradingview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here